Concepedia

Author

C.I. Rojas

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

C.I. Rojas

15

Publications

43

Citations

3

H-Index

0

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)
CR

About

C.I. Rojas is an author at Merck & Co., Inc., Rahway, NJ, USA (United States).

C.I. Rojas

×

3

Publications

34

Citations

3

H-Index

YearCitations

44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC

C.I. Rojas, Rosalyn A. Juergens, Adrian G. Sacher,

ESMO Open

2024

12

Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial

E. Felip, C.I. Rojas, M. Schenker,

Annals of Oncology

2025

12

65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC

Solange Peters, Daniel S.W. Tan, David E. Gerber,

Immuno-Oncology Technology

2024

10

Page 1